Fang Gui
Veolia Water
4 Papers
11 Citations
Fang Gui is an academic researcher from Veolia Water. The author has contributed to research in topics: Neutralization & Antibody. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages
Xiaoman Li,Yongbing Pan,Qiangling Yin,Zejun Wang,Sisi Shan,Laixing Zhang,Jinfang Yu,Yuan-Qing Qu,Lina Sun,Fang Gui,Jia Lu,Zhaofei Jing,Wei Wu,Tao Huang,Xuanling Shi,Jiandong Li,Xinguo Li,Dexin Li,Shiwen Wang,Maojun Yang,Linqi Zhang,Kai Duan,Mifang Liang,Xiaoming Yang,Xinquan Wang +24 more
TL;DR: In this paper , the authors characterized the previously reported F61, which was isolated from convalescent patients infected with prototype SARS-CoV-2, as a broadly neutralizing antibody against all VOCs including Omicron BA.1, BA.2 and BA.4 sublineages by utilizing antigen binding and cell infection assays.
Effects of Exogenous Carbon Monoxide Releasing Molecules on the Development of Zebrafish Embryos and Larvae.
TL;DR: Zebrafish larval development was disrupted at concentrations exceeding 50 μmol/L, resulting in embryonic developmental toxicity, and the use of exogenous carbon monoxide releasing molecules provides promise for clinical application.
7
Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages
Xiaoman Li,Yongbing Pan,Qiangling Yin,Zejun Wang,Sisi Shan,Laixing Zhang,Jinfang Yu,Yuan-Qing Qu,Lina Sun,Fang Gui,Jia Lu,Zhaofei Jing,Wei Wu,Tao Huang,Xuanling Shi,Jiandong Li,Xinguo Li,Dexin Li,Shiwen Wang,Maojun Yang,Linqi Zhang,Kai Duan,Mifang Liang,Xiao-Ming Yang,Xinquan Wang +24 more
TL;DR: In this article , the authors characterized the previously reported F61, which was isolated from convalescent patients infected with prototype SARS-CoV-2, as a broadly neutralizing antibody against all VOCs including Omicron BA.1, BA.2 and BA.4 sublineages by utilizing antigen binding and cell infection assays.
Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China.
Ying Liu,Jiayou Zhang,Wen Liu,Yongbing Pan,Shunan Ruan,Xu Nian,Wei Chen,Lina Sun,Qiangling Yin,Xin Yue,Qingliang Li,Fang Gui,Cong Wu,Shuzhen Wang,Yunkai Yang,Zhaofei Jing,Feiguang Long,Zejun Wang,Chaolin Huang,Kai Duan,Mifang Liang,Xiao-Ming Yang +21 more
TL;DR: The F61 nasal spray, with its favorable safety profile, could be a promising prophylactic monoclonal antibody against SARS-CoV-2 VOCs.